Dr Reddy's Laboratories Reports Modest Profit Growth Amid Pricing Pressures

Dr Reddy's Laboratories posted a 1% rise in net profit to Rs 1,410 crore for the June quarter, with revenue climbing to Rs 8,545 crore. Growth stemmed from branded markets and the Nicotine Replacement Therapy segment, despite pricing pressures on Lenalidomide in the US generics market.

Dr Reddy's Laboratories, a leading pharmaceutical company based in Hyderabad, announced a modest 1% increase in consolidated net profit, reaching Rs 1,410 crore during the June quarter.

Compared to the same period last year, when the company reported Rs 1,392 crore, this growth is attributed to strong performances in branded markets and the Nicotine Replacement Therapy segment. Revenue also saw an uptick, rising from Rs 7,673 crore to Rs 8,545 crore.

However, Dr Reddy's Co-Chairman & MD, G V Prasad, highlighted ongoing challenges, including heightened pricing pressures on Lenalidomide within the US generics market. The company remains committed to enhancing its base business through pipeline asset delivery and improved productivity. Meanwhile, shares concluded at Rs 1,247.55, marking a slight increase of 0.58% on the BSE.

(With inputs from agencies.)